Stock Financial Ratios, Dividends, Split History

NPTN / NeoPhotonics Corp, financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)285.18
Enterprise Value ($M)265.21
Book Value ($M)183.72
Book Value / Share4.12
Price / Book1.54
NCAV ($M)49.99
NCAV / Share1.12
Price / NCAV5.68
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 44,219,000
Weighted Average Number Of Shares Outstanding Basic 43,431,000
Common Shares Outstanding 44,278,392
Weighted Average Number Of Diluted Shares Outstanding 43,431,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.22
Return on Assets (ROA)-0.14
Return on Equity (ROE)-0.24
Balance Sheet (mrq) ($M)
Quick Ratio1.29
Current Ratio1.77
Income Statement (mra) ($M)
Sales Revenue Goods Net292,894,000.00
Operating Income-51.40
Net Income-53.33
Earnings Per Share Diluted-1.23
Earnings Per Share Basic-1.23
Earnings Per Share Basic And Diluted0.00
Cash Flow Statement (mra) ($M)
Cash From Operations-32.80
Cash from Investing-15.68
Cash from Financing-15.68
Identifiers and Descriptors
Central Index Key (CIK)1227025
Related CUSIPS
64051T900 64051T950

Split History

Stock splits are used by NeoPhotonics Corp, to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Intevac: Mean Reverting Value With Material Growth Opportunities

2018-07-03 seekingalpha
The Thin-film equipment division designs, manufacture, and services capital equipment that deposit thin films on the surface to produce magnetic disks for hard disk drives, centralized storage for cloud computing. Additionally, other applications and a key to material near-term growth include touch panels such as mobile phones' front and back, notebooks, smartwatch, tablets, and automotive monitors. (10-0)

Lumentum: A Diversified Growth Opportunity

2018-06-26 seekingalpha
Its a good bet for someone looking for diversified exposure to several sub-segments within the optical hardware manufacturing space. (521-0)

NeoPhotonics: Be Careful

2018-05-13 seekingalpha
Shares of NeoPhotonics (NYSE:NPTN) have pretty much been rangebound for the better part of the past six months. Bulls would believe that the company is poised to grow substantially once client spending on 100G-plus products gains momentum. That may very well be the case indeed, but there's a major risk factor that the broad swath of long-side investors is probably unaware of that can really hurt NeoPhotonics' business - its massive revenue exposure to Huawei. (44-0)

Fabrinet: Optical Communications Industry Underpriced Due To Unjustified Pessimistic Outlook

2018-05-07 seekingalpha
The optical communications industry continues to increase in size and demand for external manufacturing is becoming more common. (13-0)

CUSIP: 64051T100